BioClinica

BioClinica

BioClinica, now branded as Clario and a part of Thermo Fisher Scientific, sits inside one of the world's largest life-sciences tool companies as the dedicated clinical evidence generation unit. The Princeton-headquartered operation has been active for more than 50 years and reports involvement in over 30,000 clinical trial engagements to date. Its client base spans biotechs, contract research organizations, and large-cap pharmaceutical companies running Phase I through Phase III studies globally. The firm's deployment model fuses science-informed technology with a geographic footprint spanning 100-plus countries. It runs integrated endpoint solutions across four main asset classes: cardiac safety monitoring, medical imaging core lab services, electronic clinical outcome assessments (eCOA), and respiratory function testing. Under the imaging umbrella, modalities include CT, endoscopy, and MRI reads, supplemented by AI-driven redaction software for site-to-cloud patient data transfer. On the respiratory side, the firm offers site-based spirometry, virtual home spirometry, cough monitoring, and diffusing capacity (DLCO) assessments. The wearable-sensor division, branded Precision Motion, markets the Opal V2R research-grade sensor and links to more than 750 scientific publications that reference its clinical applications in movement disorders. In addition to its Princeton headquarters, BioClinica maintains an operational office in Montréal, Quebec. The firm is not a capital allocator in the traditional sense — it operates as a wholly owned division inside Thermo Fisher Scientific and does not disclose a separate AUM. It does not participate in fund commitments or direct equity deals beyond the internal investment required to run its nine-digit (likely) clinical technology platform. Prior to the Thermo Fisher integration, the BioClinica name functioned as a standalone contract research organization; today the parent relationship provides balance-sheet backing that supports device provisioning, 24/7 customer support, and regulatory logistics across more than 100 languages. The firm's architecture matters because it marries a clinical research organization's regulatory posture with the balance-sheet stability of a public life-sciences parent. This hybrid structure lets BioClinica place equipment, staff, and software directly into investigator sites for both fully virtual and hybrid trials, while holding the quality-management accountability that FDA and EMA submission packages demand. No external investors, no closed-end fund clock — just a permanent-capital subsidiary competing on scientific trial evidence and endpoint logistics under the Thermo Fisher umbrella.